The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents
作者： Guy Griebel , Jeanne Stemmelin , Mati Lopez-Grancha , Denis Boulay , Gerald Boquet
DOI: 10.1038/S41598-019-54557-5
关键词: Genetically modified mouse 、 Pharmacology 、 Neuroprotection 、 Programmed cell death 、 Cognitive deficit 、 GSK-3 、 Transgene 、 Hyperphosphorylation 、 Hippocampal formation 、 Medicine
摘要: … as a promising target for the treatment of Alzheimer’s disease (AD), where abnormal … , in models of neuroprotection and neuropsychiatric symptoms (NPS) associated with AD. In P301L …
nature.com
harvard.edu
sci-hub.se 参考文章(97)
Miguel Medina, Ana Castro, Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Current Opinion in Drug Discovery & Development. ,vol. 11, pp. 533- 543 ,(2008)
Chun-mei Xu, Jun Wang, Ping Wu, Yan-xue Xue, Wei-li Zhu, Qian-qian Li, Hai-feng Zhai, Jie Shi, Lin Lu, Glycogen synthase kinase 3β in the nucleus accumbens core is critical for methamphetamine-induced behavioral sensitization Journal of Neurochemistry. ,vol. 118, pp. 126- 139 ,(2011) , 10.1111/J.1471-4159.2011.07281.X
Simon Lovestone, Mercè Boada, Bruno Dubois, Michael Hüll, Juha O Rinne, Hans-Jürgen Huppertz, Miguel Calero, María V Andrés, Belén Gómez-Carrillo, Teresa León, Teodoro Del Ser, A Phase II Trial of Tideglusib in Alzheimer's Disease Journal of Alzheimer's Disease. ,vol. 45, pp. 75- 88 ,(2015) , 10.3233/JAD-141959
Christopher J. Phiel, Christina A. Wilson, Virginia M.-Y. Lee, Peter S. Klein, GSK-3α regulates production of Alzheimer's disease amyloid-β peptides Nature. ,vol. 423, pp. 435- 439 ,(2003) , 10.1038/NATURE01640
Claudie Hooper, Richard Killick, Simon Lovestone, The GSK3 hypothesis of Alzheimer's disease. Journal of Neurochemistry. ,vol. 104, pp. 1433- 1439 ,(2008) , 10.1111/J.1471-4159.2007.05194.X
Mathieu Nollet, Anne‐Marie Le Guisquet, Catherine Belzung, Models of Depression: Unpredictable Chronic Mild Stress in Mice Current Protocols in Pharmacology. ,vol. 61, ,(2013) , 10.1002/0471141755.PH0565S61
Qing-Fei Zhao, Lan Tan, Hui-Fu Wang, Teng Jiang, Meng-Shan Tan, Lin Tan, Wei Xu, Jie-Qiong Li, Jun Wang, Te-Jen Lai, Jin-Tai Yu, None, The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis Journal of Affective Disorders. ,vol. 190, pp. 264- 271 ,(2016) , 10.1016/J.JAD.2015.09.069
Mudasir Maqbool, Mohammad Mobashir, Nasimul Hoda, Pivotal role of glycogen synthase kinase-3: A therapeutic target for Alzheimer's disease European Journal of Medicinal Chemistry. ,vol. 107, pp. 63- 81 ,(2016) , 10.1016/J.EJMECH.2015.10.018
J. Prickaerts, Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania The Journal of Neuroscience. ,vol. 26, pp. 9022- 9029 ,(2006) , 10.1523/JNEUROSCI.5216-05.2006
Sheelagh FRAME, Philip COHEN, GSK3 takes centre stage more than 20 years after its discovery. Biochemical Journal. ,vol. 359, pp. 1- 16 ,(2001) , 10.1042/0264-6021:3590001